Cargando…
To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England
Autores principales: | Tugemann, Bastian, Manouchehri, Navid, Stuve, Olaf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B. V
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768009/ https://www.ncbi.nlm.nih.gov/pubmed/35078128 http://dx.doi.org/10.1016/j.msard.2022.103541 |
Ejemplares similares
-
Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
por: Manouchehri, Navid, et al.
Publicado: (2021) -
Biological Significance of Anti–SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy
por: Manouchehri, Navid, et al.
Publicado: (2020) -
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England
por: Garjani, Afagh, et al.
Publicado: (2022) -
Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
por: Manouchehri, Navid, et al.
Publicado: (2022) -
Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity
por: Manouchehri, Navid, et al.
Publicado: (2023)